Islam, Farhana http://orcid.org/0000-0003-4800-0723
Hain, Daniel http://orcid.org/0000-0001-6113-5521
Lewis, David http://orcid.org/0000-0001-5179-6967
Law, Rebecca
Brown, Lisa C. http://orcid.org/0000-0002-7719-6596
Tanner, Julie-Anne
Müller, Daniel J. http://orcid.org/0000-0003-4978-4400
Article History
Received: 3 December 2021
Revised: 3 May 2022
Accepted: 30 May 2022
First Online: 16 June 2022
Competing interests
: DH, DL, RL, LCB, and JAT were employed by Myriad Neuroscience (formerly Assurex Health) at the time of this study. DJM was a co-inventor on two patents assessing risk for antipsychotic-induced weight gain at the time of this study and was also a co-investigator on two pharmacogenetic studies where genetic test kits were provided as in-kind contribution by Myriad Neuroscience but did not receive any salary, equity, stocks, or options from any pharmacogenetic companies. All other authors declare no conflicts of interest in relation to this work.